IX Biopharma's (SGX:42C) net loss narrowed to SG$6.3 million for the half year ended Dec. 31, 2024, from SG$7.3 million a year earlier, a filing with the Singapore Exchange said on Friday.
Basic loss per share came in at SG$0.0072 from SG$0.0096 in the comparable period.
Revenue jumped 39% year over year to SG$3.7 million from SG$2.7 million, driven by stronger sales of medicinal cannabis products and services in Australia.
免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。